Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease
Ovarian cancers (OvC) are frequent, with more than 22,000 new cases each year for 14,000 deaths in the United States. Except for patients with <i>BRCA1</i> or <i>BRCA2</i> mutations, diagnostic methods, prognostic tools, and therapeutic strategies have not much improved in th...
Main Authors: | Roxane Mari, Emilie Mamessier, Eric Lambaudie, Magali Provansal, Daniel Birnbaum, François Bertucci, Renaud Sabatier |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/6/774 |
Similar Items
-
Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer
by: Xianliang Cheng, et al.
Published: (2017-11-01) -
Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?
by: Wei Zhang, et al.
Published: (2017-02-01) -
Liquid Biopsy in Cervical Cancer: Hopes and Pitfalls
by: Paola Cafforio, et al.
Published: (2021-08-01) -
Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers
by: Giovanni Vicidomini, et al.
Published: (2020-10-01) -
Application of liquid biopsy for surgical management of pancreatic cancer
by: Minako Nagai, et al.
Published: (2020-05-01)